Correction: CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer

Affiliations

• ¹ Microenvironment and Biomarkers of Solid Tumors Unit, Department of Experimental Oncology, Amadeolab Fondazione IRCCS Istituto Nazionale Dei Tumori Di Milano, Milan, Italy.
• ² Tumor Immunology Unit, Department PROMISE, Universita' Di Palermo, Palermo, Italy.
• ³ Breast Cancer Unit Clinical Translational and Immunotherapy Research, Department of Medical Oncology, IRCCS Ospedale San Rafaele, Milan, Italy.
• ⁴ Molecular Immunology Unit, Department of Experimental Oncology, Amadeolab Fondazione IRCCS Istituto Nazionale Dei Tumori Di Milano, Milan, Italy.
• ⁵ Department of Pharmacologicaland, Biomolecular Sciences "Rodolfo Paoletti",, Università Di Milano, Milan, Italy.
• ⁶ Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori Di Milano, Milan, Italy.
• ⁷ Department of Biomedical and Clinical Sciences, Università Di Milano, Milan, Italy.
• ⁸ Surgery Department, Istituti Clinici Scientifci Maugeri IRCCS, Pavia, Italy.
• ⁹ Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Dei Tumori Di Milano, Milan, Italy.
• ¹⁰ Department of Oncology and Hemato-Oncology, Universita' Di Milano, Milan, Italy.
• ¹¹ IFOM ETS, The AIRC Institute of Molecular Oncology, Milan, Italy.
• ¹² Microenvironment and Biomarkers of Solid Tumors Unit, Department of Experimental Oncology, Amadeolab Fondazione IRCCS Istituto Nazionale Dei Tumori Di Milano, Milan, Italy. Serenella.Pupa@istitutotumori.mi.it.